136624-42-5

Basic information

• Product Name: 4-AMINO-1-BENZYLPIPERIDINE-4-CARBONITRILE
• Synonyms: 4-AMINO-1-BENZYLPIPERIDINE-4-CARBONITRILE;4-Piperidinecarbonitrile, 4-amino-1-(phenylmethyl)-
• CAS NO: 136624-42-5
• Molecular Formula: C₁₃H₁₇N₃
• Molecular Weight: 215.3
• Mol File: 136624-42-5.mol

Chemical Properties

• Boiling Point: 358.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.22±0.10(Predicted)
• CAS DataBase Reference: 4-AMINO-1-BENZYLPIPERIDINE-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-1-BENZYLPIPERIDINE-4-CARBONITRILE(136624-42-5)
• EPA Substance Registry System: 4-AMINO-1-BENZYLPIPERIDINE-4-CARBONITRILE(136624-42-5)

Safety Data

• Hazardous Substances Data: 136624-42-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-1-benzylpiperidine-4-carbonitrile is used as a key intermediate in the synthesis of various pharmaceutical substances for its potential to contribute to the development of antipsychotics, antidepressants, and analgesics. Its unique structure and functional groups enable the creation of new therapeutic agents with improved efficacy and safety profiles.
Used in Drug Discovery and Development:
As a precursor in the production of novel drug candidates, 4-Amino-1-benzylpiperidine-4-carbonitrile is utilized in the exploration of new chemical entities with potential therapeutic applications. Its versatility as a chemical intermediate aids researchers in the design and synthesis of innovative pharmaceutical compounds, enhancing the drug discovery process and contributing to advancements in medicinal chemistry.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 143-33-9 sodium cyanide 
• 7677-24-9 trimethylsilyl cyanide 
• 773837-37-9 sodium cyanide 
• 151097-12-0 4-aminomethyl-1-benzylpiperidine-4-ylamine 
• 151-50-8 potassium cyanide 

Downstream Products

• 1579515-54-0 (R)-8-acetyl-2-(4-bromophenyl)-3-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579514-80-9 (R)-2-(4-bromophenyl)-3-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 
• 1579514-59-2 (R)-2-(4-(1H-indol-5-yl)phenyl)-8-benzyl-3-((1-(cyclopropanecarbonyl) pyrrolidin-3-yl)methyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one 

Relevant articles and documents

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.

Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor

We report the synthesis of rigid spirocyclic systems as conformationally constrained variants of the Ala-Phe-NH2 dipeptide amide C-terminus of the calcitonin gene-related peptide (CGRP). CGRP receptor antagonists containing these moieties displ

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Organic Compounds

A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors

The synthesis and in vitro activities of a series of succinyl-nitrile-based inhibitors of Cathepsin S are described. Several members of this class show nanomolar inhibition of the target enzyme as well as cellular potency. The inhibitors displaying the greatest potency contain N-alkyl substituted piperidine and pyrrolidine rings spiro-fused to the α-carbon of the P1 residue.

Spiro-rifamycin derivatives targeting RNA polymerase

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.

SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS

Compounds within the genus represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: T is substituted phenyl or substituted pyridyl; R is H, methyl, ethyl, -CH2CN, -CH2C(O)NH2, -(CH2)3SO3H, -CH2C(O)NHCH3, -CH2C(O)NHOH, -CH2C(O)NHOCH3, -CH2C(O)NHCH2CN, -CH2F, -CH2C(O)NHCH2SO3H, (a), (b), (c), (d) or (e); R is methyl or ethyl; and Z is substituted piperidinyl.